ClinicalTrials.Veeva

Menu
D

Dermatology Associates of Plymouth Meeting | Plymouth Meeting, PA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ruxolitinib
CTP-543
Amlitelimab
Povorcitinib
Baricitinib
Upadacitinib
Dupilumab
LY3009104
CLS006
Difamilast

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 17 total trials

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (BRAVE-AA1)

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the...

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo
Locations recently updated

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A
Locations recently updated

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Placebo
Drug: Povorcitinib
Locations recently updated

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.

Enrolling
Non-segmental Vitiligo
Drug: Vehicle Gel
Drug: VYN201 Gel

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Enrolling
Prurigo
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

Trial sponsors

Incyte logo
Concert Pharmaceuticals logo
Sanofi logo
AbbVie logo
Acrotech Biopharma logo
Genentech logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
Maruho logo
Vyne Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems